TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04028947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty
Description: Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
Study: NCT04477733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol Injection
Description: Inject 10 μg/kg of butorphanol, then propofol is injected until the patient's eyelash reflex disappears before performing colonoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Inject saline and propofol until the patient's eyelash reflex disappears before performing colonoscopy
Study: NCT03385616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gala Airway Treatment System
Description: The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
Study: NCT04297475

Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-modal photoacoustic/ultrasonic (PA/US) imaging system
Description: The multi-modal PA/US imaging system is equipped with a handheld 3D PA/US probe, and able to provide 3D volume data of dual-wavelength PA imaging of small joints, in addition to real-time 2D PA/US imaging.
Study: NCT03146728

Intervention type: OTHER
Intervention: exercise
Description: energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
Study: NCT04234503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ethics Quarter
Description: In the intervention, nurse managers have two educational packages per week, one taking 15 minutes (one quarter).The structure of the whole intervention is made according to the dimensions of ethical activity profile of nurse managers (Laukkanen et al. a2016; Laukkanen et al b2016) consisting of managers:~1. Developing of own ethics knowledge,~2. Influencing ethical issues,~3. Conducting/implementing ethics research,~4. Identifying and~5. Solving ethical problems.~Intervention includes also orientation and summary, in total 12 educational packages.~After every dimension, NMs have to make self-reflection and development plans, in total five times. This provides them the opportunity to link their everyday experience with ethical theory.
Study: NCT04206709

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic effort
Description: Active upper limbs pedaling while maintaining a pulse calculated to be approximately 60% of the predicted maximum heart rate of each patient for 20 minutes.
Study: NCT03338569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Continuous infusion of vitamin C

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo designed to mimic intervention
Study: NCT04344535

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Convalescent Plasma
Description: 450-550 mL of plasma containing anti-SARS-CoV-2 antibody titer ideally \> 1:320, but meeting minimum titer per FDA Guidelines for convalescent plasma.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Donor Plasma
Description: 450-550 mL of plasma with low titer to anti-SARS-CoV-2 antibodies
Study: NCT03729622

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low FODMAP Diet
Description: Both arms will receive the intervention but at different time points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Both arms will receive the intervention but at different time points.
Study: NCT04206709

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive pedaling
Description: 20 minutes passive pedaling by upper limbs.
Study: NCT02450097

Intervention type: OTHER
Group type: OTHER
Intervention: Caloric restriction
Study: NCT02483598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
Study: NCT01029613

Intervention type: DRUG
Intervention: Adalimumab
Description: sc. inj. Humira 40 mg every other week from week 0 to 52
Study: NCT02483598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone and Grapefruit Juice
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Study: NCT00866333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat tablets
Study: NCT00946894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Description: Total thyroidectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dunhill operation
Description: Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral subtotal thyroidectomy
Description: Bilateral subtotal thyroidectomy
Study: NCT02441751

Intervention type: PROCEDURE
Intervention: intra-operative blood loss
Description: surgery in the urology and orthopedics
Study: NCT01309984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lusedra
Description: Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge \[up to 24 hours\], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
Study: NCT01528137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: talactoferrin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01160835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplastyinstruments
Description: Quadriceps-sparing arthrotomy with side-cutting instruments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplastyinstruments
Description: Quadriceps-sparing arthrotomy with side-cutting instruments
Study: NCT01388504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
Study: NCT04015778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg Q2W or 360mg Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg Q2W or 360mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5, d1 every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 135 mg/m2, d1, 8
Study: NCT03213925

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)
Study: NCT01916902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor- Delayed Administration
Description: Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor- Immediate Administration
Description: Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Study: NCT01564641

Intervention type: DEVICE
Intervention: iDuo G2
Description: single comparator
Study: NCT03667027

Intervention type: DEVICE
Intervention: Respiratory support
Description: Mechanical ventilation or extracorporeal life support
Study: NCT01770067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CITA-RNPT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of infected CIED
Study: NCT03558841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with the THERA-Trainer Lyra
Description: Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
Study: NCT02245113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diets
Description: Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diets
Description: Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diets
Description: Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
Study: NCT02483598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone and Grapefruit Juice
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Study: NCT02886169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat meal with Sacha Inchi
Description: Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high saturated fat meal
Description: Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
Study: NCT02970305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken as two tablets, once daily by mouth
Study: NCT02207036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook intervention
Description: 90 days of Facebook messaging, weekly Ask the Doctor sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokefree.gov
Description: referral to the NCI Smokefree.gov website
Study: NCT00270647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Description: 50 mg Lurotin or placebo on alternate days (provided by BASF)
Study: NCT02624375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Live
Study: NCT04897685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flow with Nature
Description: Nature-based intervention was facilitated by a health care professional and included 12 x 90 mins sessions within 12 weeks.
Study: NCT01538992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard steerable Marinr RF ablation Catheter (5F or 7F)
Description: Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
Study: NCT01220856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: Reparixin + immunosuppression
Study: NCT03726983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
Study: NCT04306549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk-Fill and Microhybrid Composite Resins
Description: Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk-Fill and Microhybrid Composite Resins
Description: Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulk-Fill and Microhybrid Composite Resins
Description: Clinical Comparison of Composite Restorations (Two Bulk-Fill and one Microhybrid Composite Resin) to the USPHS Criterias
Study: NCT03628690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BandGrip
Description: Topical skin closure device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Wound closure
Study: NCT04815785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaurusOne® transcatheter aortic valve replacement system
Description: The TaurusOne® Transcatheter Aortic Valve System consists of an aortic valve, an associated delivery catheter and a loading system. The aortic valve consists of a self-expanding nitinol frame, a sealing skirt and valve leaflets, which are made of bovine pericardium. The delivery system is mainly composed of conical head, opacity ring, inner tube, top ring, middle tube, outer tube, booster rod, stress diffusion catheter, handle, etc. The outflow end of the aortic valve is provided with three fixing holes evenly distributed on the circumference on the top ring of the delivery catheter, so as to facilitate the installation, delivery and release of the aortic valve. Before the operation, the aortic valve needs to be installed into the sheath of the delivery catheter as required.
Study: NCT04641416

Intervention type: DIAGNOSTIC_TEST
Intervention: Routinely performed echo, ECG and hemodynamic monitoring
Description: The pump data of patients on the ICU or normal ward are stored in a continuous data acquisition system (CDAS) on a notebook which is operated in battery operation, and analyzed afterwards with a mat-lab based software. For outpatients a mobile data-recorder will allow a continuous data acquisition for a period up to 2 months on a SD card. During this non-invasive pump data monitoring, routinely available hemodynamic monitoring, ECG and echo data will be collected.
Study: NCT02176837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrite
Description: Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
Study: NCT04360434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI006
Description: NI006 will be administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
Study: NCT00618917

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Manganese Superoxide Dismutase Plasmid Liposome
Description: 15 ml of liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy to stop the growth of tumor cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Chemotherapy to stop the growth of tumor cells. This drug kills tumor cells by inducing multipolar divisions. Cells entering mitosis in the presence of concentrations of paclitaxel equivalent to those in human breast tumors form abnormal spindles that contain additional spindle poles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
Study: NCT04452409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser
Description: The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Mediterranean diet
Description: recommend healthy diet component evaluated periodically by 24 hour recall

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: recommend healthy diet component evaluated periodically by 24 hour recall
Study: NCT01458964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
Study: NCT01218425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Description: Oral dose 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 125 mg
Description: oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidon 10 mg
Description: Domperidon 10 mg
Study: NCT00528710

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SAM-e (S-Adenosyl-L-Methionine)
Description: One 400 mg tablet daily in the morning.
Study: NCT03897361

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST)
Description: Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS or pCDY.EFS.CTNS.T260I, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
Study: NCT04498988

Intervention type: OTHER
Intervention: Observational study without interventions

Intervention type: OTHER
Intervention: Observational study without interventions

Intervention type: OTHER
Intervention: Observational study without interventions
Study: NCT04320953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-contact MCE system
Description: After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination.
Study: NCT02277067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
Study: NCT01717391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorothymidine F 18
Description: A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
Study: NCT00695825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low GI+high GI
Description: Consumption of low GI food product on day 1 Consumption of high GI food product on day 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI+low GI
Description: Consumption of high GI food product on day 1 Consumption of low GI food product on day 2